Australia - engleză - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac - cephalexin as monohydrate(150mg/ml) - parenteral liquid/solution/suspension - antibiotic - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - erysipelothrix rhusiopathiae | escherichia coli (e. coli) | haemophilus spp. | infections of the gastrointestinal tract | infections of the respiratory tract | infections of the urogenital tract | klebsiella spp. | localised infections in soft tissue | pasteurella spp. | proteus mirabilis | salmonella spp. | staphylococcus spp. | streptococcus spp. | systemic infection | acute respiratory infections | bronchiseptica | bronchitis | cystitis | haemophilus agni | haemophilus bovis | haemophilus parainfluenzae | haemophilus parasuis | haemophilus pleuropneumoniae | haemophilus somnus | haemophilus suis | including b-lactamase producin | metritis | nephritis | pasterellosis | pasteurellosis | pharyngitis | pneumonia | staphylococcosis | tonsillitis

Australia - engleză - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cefalexin monohydrate, quantity: 262.94 mg (equivalent: cefalexin, qty 250 mg) - capsule - excipient ingredients: colloidal anhydrous silica; magnesium stearate; lactose; titanium dioxide; brilliant blue fcf; purified water; quinoline yellow; allura red ac; gelatin; sodium lauryl sulfate - cephalexin is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms:,- respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.),- bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only),- otitis media due to s. pneumoniae, staphylococci,- skin and soft-tissue infections caused by staphylococci and/or streptococci,- genitourinary tract infections, including acute prostatitis caused by e. coli, p. mirabilis, and klebsiella sp.,the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions.,note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cefalexin monohydrate, quantity: 525.87 mg (equivalent: cefalexin, qty 500 mg) - capsule - excipient ingredients: magnesium stearate; colloidal anhydrous silica; lactose; titanium dioxide; brilliant blue fcf; quinoline yellow; purified water; gelatin; sodium lauryl sulfate - cephalexin is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms:,- respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.),- bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only),- otitis media due to s. pneumoniae, staphylococci,- skin and soft-tissue infections caused by staphylococci and/or streptococci,- genitourinary tract infections, including acute prostatitis caused by e. coli, p. mirabilis, and klebsiella sp.,the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions.,note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cefalexin monohydrate, quantity: 262.94 mg (equivalent: cefalexin, qty 250 mg) - capsule - excipient ingredients: lactose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; brilliant blue fcf; purified water; quinoline yellow; allura red ac; gelatin; sodium lauryl sulfate - cephalexin is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms:,- respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.),- bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only),- otitis media due to s. pneumoniae, staphylococci,- skin and soft-tissue infections caused by staphylococci and/or streptococci,- genitourinary tract infections, including acute prostatitis caused by e. coli, p. mirabilis, and klebsiella sp.,the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions.,note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cefalexin monohydrate, quantity: 525.87 mg (equivalent: cefalexin, qty 500 mg) - capsule - excipient ingredients: lactose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; brilliant blue fcf; quinoline yellow; purified water; gelatin; sodium lauryl sulfate - cephalexin is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms:,- respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.),- bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only),- otitis media due to s. pneumoniae, staphylococci,- skin and soft-tissue infections caused by staphylococci and/or streptococci,- genitourinary tract infections, including acute prostatitis caused by e. coli, p. mirabilis, and klebsiella sp.,the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions.,note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cefalexin monohydrate, quantity: 262.94 mg (equivalent: cefalexin, qty 250 mg) - capsule - excipient ingredients: lactose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; brilliant blue fcf; purified water; quinoline yellow; allura red ac; gelatin; sodium lauryl sulfate - cephalexin is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms:,- respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.),- bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only),- otitis media due to s. pneumoniae, staphylococci,- skin and soft-tissue infections caused by staphylococci and/or streptococci,- genitourinary tract infections, including acute prostatitis caused by e. coli, p. mirabilis, and klebsiella sp.,the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions.,note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cefalexin monohydrate, quantity: 525.87 mg (equivalent: cefalexin, qty 500 mg) - capsule - excipient ingredients: lactose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; brilliant blue fcf; quinoline yellow; purified water; gelatin; sodium lauryl sulfate - cephalexin is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms:,- respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.),- bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only),- otitis media due to s. pneumoniae, staphylococci,- skin and soft-tissue infections caused by staphylococci and/or streptococci,- genitourinary tract infections, including acute prostatitis caused by e. coli, p. mirabilis, and klebsiella sp.,the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions.,note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

unit dose services - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 250 mg - cephalexin capsules, usp are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms:   respiratory tract infections caused by and (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever.   cephalexin capsules, usp are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin capsules, usp in the subsequent prevention of rheumatic fever are not available at present.)   otitis media due to , , , and   skin and skin structure infections caused by and/or   bone infections caused by and/or   genitourinary tract infections, including acute prostatitis, caused by , , and   — culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated.   to reduce the development of drug-resistant bacteria and maint

Australia - engleză - APVMA (Australian Pesticides and Veterinary Medicines Authority)

jurox pty limited - cephalexin as cephalexin monohydrate - oral tablet - cephalexin as cephalexin monohydrate antibiotic active 75.0 mg/tb - antibiotic & related - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - infections of soft cutaneous tissue | infections of the digestive tract | infections of the respiratory tract | infections of the urinary tracts | osteomyelitis | acute respiratory infections | bronchiseptica | bronchitis | escherichia coli | group d streptococcus | klebsiella spp. | pharyngitis | pneumonia | proteus spp. | pseudomonas aeruginosa | staphylococcus spp. | tonsillitis

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin for oral suspension is indicated for the treatment of respiratory tract infections caused by susceptible isolates of streptococcus pneumoniae and streptococcus pyogenes . cephalexin for oral suspension is indicated for the treatment of otitis media caused by susceptible isolates of streptococcus pneumoniae , haemophilus influenzae , staphylococcus aureus , streptococcus pyogenes , and moraxella catarrhalis . cephalexin for oral suspension is indicated for the treatment of skin and skin structure infections caused by susceptible isolates of the following gram-positive bacteria: staphylococcus aureus and streptococcus pyogenes . cephalexin for oral suspension is indicated for the treatment of bone infections caused by susceptible isolates of staphylococcus aureus and proteus mirabilis. cephalexin for oral suspension is indicated for the treatment of genitourinary tract infections, including acute prostatitis, caused by susceptible isolates of escherichia coli , proteus mirabilis , and klebsiella p